AU2007278894B2 - Cytokine derivatives - Google Patents

Cytokine derivatives Download PDF

Info

Publication number
AU2007278894B2
AU2007278894B2 AU2007278894A AU2007278894A AU2007278894B2 AU 2007278894 B2 AU2007278894 B2 AU 2007278894B2 AU 2007278894 A AU2007278894 A AU 2007278894A AU 2007278894 A AU2007278894 A AU 2007278894A AU 2007278894 B2 AU2007278894 B2 AU 2007278894B2
Authority
AU
Australia
Prior art keywords
seq
agents
treating
hiv
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007278894A
Other languages
English (en)
Other versions
AU2007278894A1 (en
Inventor
Oliver Hartley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Biotechnology Switzerland SARL
Original Assignee
Orion Biotechnology Switzerland SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Biotechnology Switzerland SARL filed Critical Orion Biotechnology Switzerland SARL
Publication of AU2007278894A1 publication Critical patent/AU2007278894A1/en
Assigned to MINTAKA FOUNDATION FOR MEDICAL RESEARCH reassignment MINTAKA FOUNDATION FOR MEDICAL RESEARCH Alteration of Name(s) of Applicant(s) under S113 Assignors: THE MINTAKA MEDICAL RESEARCH FOUNDATION
Application granted granted Critical
Publication of AU2007278894B2 publication Critical patent/AU2007278894B2/en
Assigned to ORION Biotechnology Switzerland Sarl reassignment ORION Biotechnology Switzerland Sarl Request for Assignment Assignors: MINTAKA FOUNDATION FOR MEDICAL RESEARCH
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
AU2007278894A 2006-07-25 2007-07-25 Cytokine derivatives Active AU2007278894B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0614755.7 2006-07-25
GBGB0614755.7A GB0614755D0 (en) 2006-07-25 2006-07-25 Cytokine derivatives
PCT/IB2007/003026 WO2008012689A2 (en) 2006-07-25 2007-07-25 Cytokine derivatives

Publications (2)

Publication Number Publication Date
AU2007278894A1 AU2007278894A1 (en) 2008-01-31
AU2007278894B2 true AU2007278894B2 (en) 2012-08-09

Family

ID=37006114

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007278894A Active AU2007278894B2 (en) 2006-07-25 2007-07-25 Cytokine derivatives

Country Status (25)

Country Link
US (2) US8686111B2 (enExample)
EP (1) EP2076532B1 (enExample)
JP (1) JP5224603B2 (enExample)
KR (1) KR101530353B1 (enExample)
CN (1) CN101511867B (enExample)
AT (1) ATE490270T1 (enExample)
AU (1) AU2007278894B2 (enExample)
BR (1) BRPI0715331B8 (enExample)
CA (1) CA2658806C (enExample)
CY (1) CY1111630T1 (enExample)
DE (1) DE602007010969D1 (enExample)
DK (1) DK2076532T3 (enExample)
ES (1) ES2361455T3 (enExample)
GB (1) GB0614755D0 (enExample)
HR (1) HRP20110146T1 (enExample)
ME (1) ME01320B (enExample)
MX (1) MX2009000918A (enExample)
NZ (1) NZ575092A (enExample)
PL (1) PL2076532T3 (enExample)
PT (1) PT2076532E (enExample)
RS (1) RS51854B (enExample)
RU (1) RU2461567C2 (enExample)
SI (1) SI2076532T1 (enExample)
WO (1) WO2008012689A2 (enExample)
ZA (1) ZA200901342B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600091033A1 (it) * 2016-09-08 2018-03-08 Bioimmunizer Sagl Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti.
US20210205412A1 (en) * 2018-05-28 2021-07-08 Université De Genève Methods of inhibiting cerebral inflammation
US20210205411A1 (en) * 2018-05-28 2021-07-08 Orion Biotechnology Switzerland Sàrl Ccr5 inhibitor for use in treating cancer
EP4646232A1 (en) 2023-01-06 2025-11-12 Université de Genève Variant ligand conjugates for payload delivery
WO2025172252A1 (en) 2024-02-15 2025-08-21 Novo Nordisk A/S Protracted ccr5 antagonists and uses thereof
WO2025176787A1 (en) 2024-02-22 2025-08-28 Orion Biotechnology Holding Sa Ccl5 variants for modulating gpr75
WO2025186255A1 (en) 2024-03-06 2025-09-12 Orion Biotechnology Holding Sa Gipr inhibitors and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022884A2 (en) * 2001-09-05 2003-03-20 Universite Pierre Et Marie Curie (Paris Vi) Methods for construction and screening of libraries of chemokine variants

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960703136A (ko) * 1993-06-09 1996-06-19 미첼 클레인 탠덤 합성 hiv-1 펩티드들
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
US7442512B2 (en) 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2005112567A2 (en) 2004-05-03 2005-12-01 University Of Maryland Biotechnology Institute Vaginal microbicide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022884A2 (en) * 2001-09-05 2003-03-20 Universite Pierre Et Marie Curie (Paris Vi) Methods for construction and screening of libraries of chemokine variants

Also Published As

Publication number Publication date
DE602007010969D1 (de) 2011-01-13
US20090317363A1 (en) 2009-12-24
BRPI0715331B8 (pt) 2021-05-25
CA2658806C (en) 2017-01-03
ATE490270T1 (de) 2010-12-15
US20130330305A1 (en) 2013-12-12
KR101530353B1 (ko) 2015-06-26
ES2361455T3 (es) 2011-06-17
GB0614755D0 (en) 2006-09-06
RU2461567C2 (ru) 2012-09-20
US8686111B2 (en) 2014-04-01
CN101511867B (zh) 2014-04-09
JP5224603B2 (ja) 2013-07-03
EP2076532A2 (en) 2009-07-08
BRPI0715331B1 (pt) 2021-04-13
HRP20110146T1 (hr) 2011-06-30
DK2076532T3 (da) 2011-03-07
EP2076532B1 (en) 2010-12-01
CA2658806A1 (en) 2008-01-31
AU2007278894A1 (en) 2008-01-31
NZ575092A (en) 2011-08-26
CY1111630T1 (el) 2015-10-07
CN101511867A (zh) 2009-08-19
KR20090060281A (ko) 2009-06-11
RU2009106436A (ru) 2010-08-27
HK1131162A1 (en) 2010-01-15
MX2009000918A (es) 2009-08-26
ME01320B (me) 2013-12-20
US9328153B2 (en) 2016-05-03
WO2008012689A2 (en) 2008-01-31
RS51854B (sr) 2012-02-29
BRPI0715331A2 (pt) 2013-07-16
WO2008012689A3 (en) 2008-05-08
PL2076532T3 (pl) 2011-07-29
ZA200901342B (en) 2010-11-24
SI2076532T1 (sl) 2011-06-30
PT2076532E (pt) 2011-03-02
JP2009544304A (ja) 2009-12-17

Similar Documents

Publication Publication Date Title
US9328153B2 (en) Cytokine derivatives
ES2273492T3 (es) Peptidos antagonistas de il-6.
JP2001520673A (ja) 免疫不全ウイルス感染を阻害するケモカイン類およびそれに基づいた方法
AU750341B2 (en) Amino-terminally truncated rantes as chemokine antagonists
JP2004537964A (ja) インターフェロン、それに関する使用及び組成物
CN103626865B (zh) 具有趋化活性的分泌蛋白及其编码序列和医药用途
HK1131162B (en) Cytokine derivatives
AU734252B2 (en) Novel mouse CXC chemokine receptor
US20030138400A1 (en) Short forms of chemokine beta-8
JP2000198798A (ja) 抗ｃｃｒ５抗体認識ペプチドミミックス、その製造方法およびその用途

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ FROM HARTLEY, OLIVIER TO HARTLEY, OLIVER

TH Corrigenda

Free format text: IN VOL 23, NO 26, PAGE(S) 8941 UNDER THE HEADING CHANGE OF NAMES(S) OF APPLICANT(S), SECTION 104 - 2007 UNDER THE NAME THE MINTAKA MEDICAL RESEARCH FOUNDATION, APPLICATION NUMBER 2007278894, UNDER INID(71), CORRECT THE NAME TO READ MINTAKA FOUNDATION FOR MEDICAL RESEARCH

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ORION BIOTECHNOLOGY SWITZERLAND SARL

Free format text: FORMER OWNER(S): MINTAKA FOUNDATION FOR MEDICAL RESEARCH